Deliver Your News to the World

SmallCapNewsRelease:(OTC:KKUR) Announces Flawless Test Of Its Technology


JERICHO, NY--(SmallCapNewsRelease)--January 14th, 2009, ChromoCure Inc., (OTC:KKUR) announced today that they have published a pre-clinical system test and performance assessment on cervical cancer with a major cancer clinic.

The study demonstrated the correctness and the accuracy of ChromoCure’s approach to cancer detection via aneuploidy basis which was recently back by Mayo Clinic research.

The company’s systems detect the single characteristic found in 100% of all cancers at all stages, and never found in normal cells. The company therefore believes its technology detects cancer with an effective 100% specificity and effective 100% accuracy. The Company’s technology also objectively measures, with high precision, the level of cancer present and its stage of progression.

To view the entire press release, please visit

SmallCapNewsRelease gainers are Cardica Inc (NASDAQ:CRDC) Labranche & Co (NYSE:LAB) ParkerVision Inc (NASDAQ:PRKR) TerreStar Corp (NASDAQ:TSTR) Peoples Educational Holdings (NASDAQ:PEDH) RealNetworks Inc (NASDAQ:RNWK) Wave Systems Corp (NASDAQ:WAVX) First Federal of Northern Michigan (NASDAQ:FFNM)

SmallCapNewsRelease decliners are Rosetta Genomics (NASDAQ:ROSG) MDRNA Inc (NASDAQ:MRNA) Westway Group (NASDAQ:WWAY) Medifast Inc (NYSE:MED) Cell Therapeutics Inc (NASDAQ:CTIC) Bay National Corp (NASDAQ:BAYN) Westwood One Inc (NASDAQ:WWON) Converted Organics (NASDAQ:COINU)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Small Cap News Release twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation, do no trading of any kind and send no faxes or emails.


 Cervical Cancer
 Penny Stock
 Small Cap News

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.